Evidence map›Paper›PMID 30411024›Full record

ArticleACS omega2018

Enhanced Cancer Theranostics with Self-Assembled, Multilabeled siRNAs.

Stephen D Kozuch, Christopher N Cultrara, Adah E Beck, Claudia J Heller, Sunil Shah, Mayurbhai R Patel, Jenny Zilberberg, David Sabatino

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Solid Phase Chemical Synthesis of RNA.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Stephen D KozuchDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
Christopher N CultraraDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
Adah E BeckDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
Claudia J HellerDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
Sunil ShahDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
Mayurbhai R PatelDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
Jenny ZilberbergDepartment of Biomedical Research, Hackensack University Medical Center, Hackensack, New Jersey 07601, United States.
David SabatinoDepartment of Chemistry and Biochemistry, Seton Hall University, South Orange, New Jersey 07079, United States.
Seton Hall University · USHackensack University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integration of therapy and diagnostics, termed "theranostics", has recently gained widespread utility in the development of new and improved therapeutics that effectively diagnose and treat diseases, such as cancer. In this study, the covalent attachment of multiple fluorescent labels (i.e., fluorescein isothiocyanate (FITC)) to a wide range of siRNAs, including those adopting linear, V- and Y-shape nanostructures, was successfully accomplished by solid-phase bioconjugation for monitoring cell uptake, co-localization, and biological activity in cell culture. The FITC-labeled higher-order V- and Y-shape siRNAs maintained the requisite hybrid stabilities and A-type helical structures for invoking RNAi activity. The FITC-siRNA hybrids with sense-strand modifiers enabled efficient mRNA knockdown (∼50-90%), which also translated to increased cell death (∼20-95%) in a bone metastatic prostate cancer cell line, over a 72 h incubation period. Significantly, the Y-shaped siRNA containing three FITC probes enhanced fluorescent signaling relative to the siRNA constructs containing single and double fluorophores while retaining potent knockdown and cell death effects post-transfection. Taken together, this data highlights the theranostic utility of the multilabeled FITC-siRNA constructs for potential cancer gene therapy applications.

Identifiers

PMID30411024
PMCPMC6217585
OpenAlexW2896843656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.